🇺🇸 FDA
Patent

US 7501501

MHC-Class II restricted melanoma antigens and their use in therapeutic methods

granted A61KA61K39/00

Quick answer

US patent 7501501 (MHC-Class II restricted melanoma antigens and their use in therapeutic methods) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Mar 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Mar 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K39/00